Compare Nutanix Inc (NTNX) vs Novavax Inc (NVAX) Price & Performance

Nutanix (NTNX) trades at $67.49, down 0.84% on the day, with strong technical indicators showing a bullish trend. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49. Recent recognition in Gartner's Magic Quadrant for container management and strong conference presentations highlight ongoing business momentum. Valuation metrics show a P/E of 12.95 and P/S of 6.85, with exceptional profitability margins including 86.8% gross margin and 52.81% net income margin.

The outlook remains positive with analyst consensus price target of $77.20 representing 14% upside potential. Key opportunities include continued hybrid cloud adoption and AI infrastructure demand, while risks involve competitive pressures and execution challenges in maintaining growth momentum. Cash flow trends show improvement with 2026 operating cash flow projected at $917 million, supporting the company's strategic investments.

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.